$7.97
+5.6%ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.
Chief Financial Officer
Compensation
$600,000
Chief Operating Officer
Compensation
$490,000
Chief Technology Officer
Global Head of HR & Director UK Nuclear Operations
Head of Engineering
Head of Research & Development
Medical Director & Chief Executive Officer of Pet Labs
President, Chief Executive Officer & Executive Chairman
Compensation
$1,010,000
During the last 12 months, insiders have purchased $1.07M and sold $6.01M worth of ASPI shares, resulting in $4.93M of net selling activity.
0
0.00
308.5K
2.31M
-2.3M
-$2.31M
162.2K
881.46K
121.9K
674.85K
+207K
+$207K
96.0K
192.00K
439.7K
3.02M
-2.8M
-$2.83M
0
0.00
0
0.00
+0
+$0
Mann Paul Elliot
Officer: Executive Chairman
$881K
Wider Todd
Director
$192K
Mann Paul Elliot
Director, Officer: Chairman And Ceo
$4.07M
Ainscow Robert
Officer: Coo
$1.29M
Kiessling Heather
Officer: Chief Financial Officer
$591K
Moore Duncan
Director
$61K
Strong bearish signal with $4.93M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
ASPI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | November 25, 2025 | December 08, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 21, 2024 | November 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 02, 2023 | November 01, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.